N-methyladenosine reader as a prognostic Biomarker contribute to malignant progression of glioma.

Background: Glioblastoma (GBM) is a highly aggressive cancer having a dismal prognosis. N-methyladenosine (mA) is closely related to GBM progression. The significance of mA modifications depends on the mA readers, whose functions in glioma progression are largely unknown.

Identification of IGF2BP3 as an Adverse Prognostic Biomarker of Gliomas.

N6-methyladenosine (mA) RNA modification can alter gene expression and function by regulating RNA splicing, stability, translocation, and translation. It is involved in various types of cancer. However, its role in gliomas is not well known.

Dexamethasone inhibits the proliferation of tumor cells.

Objective: Dexamethasone (DEX) is a glucocorticoid that is commonly used in clinics. Previously, DEX has been shown to inhibit the function of immune system; however, DEX is often used to treat side reactions, such as nausea and vomiting caused by chemotherapy in clinics. Therefore, it is necessary to study the role of DEX in the treatment of cancer.